Valeant Pharmaceuticals International has issued $650 million of senior unsecured notes. The 6.75% senior notes will mature on Aug.15, 2021. The proceeds are expected to be used to finance the buyout of pharmaceutical company, PharmaSwiss.
Valeant will also use the proceeds for the acquisition of all U.S. and Canadian rights to non-ophthalmic topical formulations of Zovirax from GlaxoSmithKline. Goldman Sachs was appointed as the sole bookrunning manager for the sale, adds Reuters.
Click here for the release from PR Newswire.
Click here for the additional coverage from Reuters.